Literature DB >> 12531922

Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences.

J Michalek1, R H Collins, H P Durrani, P Vaclavkova, L E Ruff, D C Douek, E S Vitetta.   

Abstract

Although graft-versus-host (GVH) disease (GVHD) is usually associated with graft versus leukemia (GVL), GVL can occur in the absence of clinical GVHD. There is evidence to suggest that GVL and GVH are mediated by different clones of T cells. The objective of this study was to identify the two types of T cells based on their receptor sequences. To this end we used irradiated nonleukemic cells from recipients as stimulator cells in a primary mixed leukocyte reaction (MLR). The activated CD4(+) donor T cells that expressed CD25 were purified by cell sorting. To prepare GVL-specific T cells, alloreactive T cells in the primary MLR were first depleted with an anti-CD25 immunotoxin. The remaining T cells had negligible alloreactivity in a secondary MLR. The allodepleted cells were then stimulated by using purified leukemia cells from the same individual as stimulator cells, and the CD25(+)-activated cells were purified by cell sorting. The GVL- and GVH-specific T cells were analyzed for their T cell receptor (TCR) clonality by using anchored RT-PCR of all the TCRbeta locus complementarity-determining region 3 (CDR3) sequences. By comparing TCRbeta CDR3 sequences from transformed bacterial colonies, we were able to demonstrate that T cells mediating GVH were different from those mediating GVL in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs. By using the appropriate TCRbeta CDR3-specific primers and probes, the GVH- and GVL-specific clones were monitored in a recipient undergoing an allogeneic stem cell transplant from her HLA-matched related donor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531922      PMCID: PMC298747          DOI: 10.1073/pnas.0337543100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape.

Authors:  Daniel C Douek; Michael R Betts; Jason M Brenchley; Brenna J Hill; David R Ambrozak; Ka-Leung Ngai; Nitin J Karandikar; Joseph P Casazza; Richard A Koup
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

2.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 3.  New strategies for preventing graft-versus-host disease.

Authors:  W J Murphy; B R Blazar
Journal:  Curr Opin Immunol       Date:  1999-10       Impact factor: 7.486

4.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

5.  Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.

Authors:  Y Z Jiang; D A Mavroudis; S Dermime; J Molldrem; N F Hensel; A J Barrett
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

6.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.

Authors:  D Montagna; E Yvon; V Calcaterra; P Comoli; F Locatelli; R Maccario; A Fisher; M Cavazzana-Calvo
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

7.  In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.

Authors:  Anne M Dickinson; Xiao-Nong Wang; Lisbet Sviland; Florry A Vyth-Dreese; Graham H Jackson; Ton N M Schumacher; John B A G Haanen; Tuna Mutis; Els Goulmy
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

8.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study.

Authors:  Isabelle André-Schmutz; Françoise Le Deist; Salima Hacein-Bey-Abina; Ellen Vitetta; John Schindler; Gaelle Chedeville; Etienne Vilmer; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

9.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

Review 10.  Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.

Authors:  J H F Falkenburg; W A F Marijt; M H M Heemskerk; R Willemze
Journal:  Curr Opin Hematol       Date:  2002-11       Impact factor: 3.284

View more
  14 in total

Review 1.  Hematopoietic stem cell transplantation for MDS.

Authors:  Matthias Bartenstein; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

2.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  Raising the spectra of T-cell profiling.

Authors:  William J Murphy
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

4.  Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies.

Authors:  Stephan Mielke; Zachariah A McIver; Aarthy Shenoy; Vicki Fellowes; Hahn Khuu; David F Stroncek; Susan F Leitman; Richard Childs; Minoo Battiwalla; Eleftheria Koklanaris; Janice Haggerty; Bipin N Savani; Katie Rezvani; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-31       Impact factor: 5.742

5.  Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome.

Authors:  Zachariah A McIver; Jan J Melenhorst; Andrew Grim; Nicholas Naguib; Gerrit Weber; Vicki Fellowes; Hahn Khuu; David S Stroncek; Susan F Leitman; Minoo Battiwalla; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-30       Impact factor: 5.742

6.  No recovery of T-cell receptor excision circles (TRECs) after non-myeloablative allogeneic hematopoietic stem cell transplantation is correlated with the onset of GvHD.

Authors:  Grzegorz K Przybylski; Karl-A Kreuzer; Wolfgang Siegert; Christian A Schmidt
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

7.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

8.  Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Authors:  Osnat Bohana-Kashtan; Sebastien Morisot; Richard Hildreth; Cory Brayton; Hyam I Levitsky; Curt I Civin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

9.  Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.

Authors:  Jian-Ming Li; Christopher T Petersen; Jing-Xia Li; Reema Panjwani; Daniel J Chandra; Cynthia R Giver; Bruce R Blazar; Edmund K Waller
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

10.  Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells.

Authors:  Stephan Fricke; Nadja Hilger; Christian Fricke; Uta Schönfelder; Gerhard Behre; Peter Ruschpler; Andreas Boldt; Christopher Oelkrug; Ulrich Sack; Frank Emmrich
Journal:  Cell Mol Life Sci       Date:  2013-09-26       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.